Royal Marsden Hospital NHS Foundation Trust
London, London .., SW3 6JJ, United Kingdom
NCT Number: NCT01851928
The objective of this study is to evaluate the sensitivity and specificity of two nutrition screening tools to identify inpatients with malnutrition or at risk of malnutrition. The two tools are the Royal Marsden Abridged Adult Nutrition Screening Tool (AANST) and the Malnutrition Screening Tool (MST)[10] The tools will be compared with the currently accepted gold standard, Patient Generated Subjective Global Assessment (PG-SGA). Both screening tools are in the form of scored questionnaires and are suitable for electronic input.
The ultimate objective is to select an adult inpatient nutrition screening tool with the highest sensitivity for future use in the oncology inpatient setting in order to allow prompt commencement of an appropriate nutrition care plan.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Observational
London, London .., SW3 6JJ, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 hrs
The primary endpoint of the study is the sensitivity of each screening tool as compared to the gold standard of PG-SGA when completed by a trained dietitian.
Time frame: 24 hrs
Secondary endpoints are as follows:
Royal Marsden NHS Foundation Trust
Other
The Validation of Two Inpatient Adult Nutrition Screening Tools in Cancer Care - a Prospective Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01582906
Adenocarcinoma of the Gastroesophageal Junction, Adnexal Diseases
London, United Kingdom
View Trial DetailsNCT01216813
Adenocarcinoma of the Gastroesophageal Junction, Adnexal Diseases
London, England, United Kingdom
View Trial DetailsNCT01498289
Adenocarcinoma Of Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Mobile, Alabama, United States
View Trial DetailsNCT00938470
Adenocarcinoma Of Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Scottsdale, Arizona, United States
View Trial Details